Gilead Sciences Inc (GILD)

69.35 +0.54  +0.78% NASDAQ Aug 7, 20:00 USD
View Full Chart
Price Chart
View All Events

Events

Date Type Description
10/23/2020 16:30 EDT Misc Gilead Sciences Inc Third Quarter Earnings Conference Call for 2020
10/23/2020 Earnings Gilead Sciences Inc Third Quarter Earnings for 2020 Release
09/14/2020 Dividends Amount: 0.68, Declared Date: Jul 30 2020, Pay Date: Sep 29 2020
07/30/2020 16:30 EDT Misc Gilead Sciences Inc Second Quarter Earnings Conference Call for 2020
07/30/2020 Earnings Gilead Sciences Inc Second Quarter Earnings Result for 2020
06/11/2020 Dividends Amount: 0.68, Declared Date: Apr 30 2020, Pay Date: Jun 29 2020
05/06/2020 10:00 PDT Misc Gilead Sciences Inc Annual General Meeting for 2019
04/30/2020 16:30 EDT Misc Gilead Sciences Inc First Quarter Earnings Conference Call for 2020
04/30/2020 Earnings Gilead Sciences Inc First Quarter Earnings Result for 2020
03/12/2020 Dividends Amount: 0.68, Declared Date: Feb 04 2020, Pay Date: Mar 30 2020
View All Performance Charts

Total Returns Comparison

Ratings & Reports

Advertisement
Edit

Profile

  • URL: https://www.gilead.com
  • Investor Relations URL: http://investors.gilead.com/phoenix.zhtml?c=69964&p=irol-irhome
  • HQ State/Province: California
  • Sector: Healthcare
  • Industry: Drug Manufacturers - General
  • Equity Style: Large Cap/Value
  • Next Earnings Release: Oct. 23, 2020
  • Last Earnings Release: Jul. 30, 2020
  • Next Ex-Dividend Date: Sep. 14, 2020
  • Last Ex-Dividend Date: Jun. 11, 2020
  • Description: Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite acquisition and pending Forty-Seven acquisition boost Gilead's exposure to cell therapy and noncell therapy in oncology.

Top Fund Holders

Symbol Name Weighting
IBB iShares Nasdaq Biotechnology ETF 6.92%
RMEBX American Funds American Mutual R2E 3.74%
RCEEX American Funds Capital Income Bldr R2E 2.42%
RICAX American Funds Invmt Co of Amer R1 2.21%
XLV Health Care Select Sector SPDR® ETF 2.18%
VHT Vanguard Health Care ETF 2.14%
WSHCX American Funds Washington Mutual C 1.50%
MTUM iShares Edge MSCI USA Momentum Fctr ETF 1.24%
USMV iShares Edge MSCI Min Vol USA ETF 1.18%
QQQ Invesco QQQ Trust 0.76%

Comparables

Edit
Advertisement

{{root.upsell.info.feature_headline}}.

{{root.upsell.info.feature_description}}

Please note that this feature is only available as an add-on to YCharts subscriptions.


Please note that this feature requires full activation of your account and is not permitted during the free trial period.

Start My Free Trial {{root.upsell.info.call_to_action}} No credit card required.

Already a subscriber? Sign in.